Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8661818 | 0.82 | CES2 (0.47) | ALOX5CES2CES1KEAP1POLB | |
| SCHEMBL11666936 | 0.80 | ALOX5 (0.46) | ALOX5CES2CES1KEAP1POLB | |
| SCHEMBL13163250 | 0.78 | ALOX5 (0.51) | ALOX5CES2CES1KEAP1POLB | |
| SCHEMBL7955355 | 0.78 | CES2 (0.61) | ALOX5CES2CES1KEAP1POLB | |
| SCHEMBL5027606 | 0.78 | ALOX5 (0.51) | ALOX5CES2CES1KEAP1POLB | |
| SCHEMBL8255644 | 0.77 | ALOX5 (0.47) | ALOX5CES2CES1KEAP1POLB | |
| SCHEMBL2370715 | 0.76 | ALOX5 (0.59) | ALOX5CES2CES1KEAP1POLB | |
| SCHEMBL9814779 | 0.76 | ALOX5 (0.50) | ALOX5CES2CES1KEAP1POLB | |
| SCHEMBL8853390 | 0.76 | ALOX5 (0.50) | ALOX5CES2CES1KEAP1POLB | |
| SCHEMBL10208107 | 0.76 | ALOX5 (0.59) | ALOX5CES2CES1KEAP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180892-A1 | THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132) | IMMUNOMEDICS, INC. | 2024-06-06 | — | — | US | disclosed |
| CN-118001422-A | Dosage of immunoconjugates of antibodies with SN-38 with improved efficacy and reduced toxicity | 免疫医疗公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240148873-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240139324-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240024489-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | INSTITUT PASTEUR (FR) | 2024-01-25 | — | — | US | disclosed |
| CN-117138060-A | New adjuvant use of antibody-drug conjugates | 免疫医疗公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3585442-B1 | THERAPY OF SMALL-CELL LUNG CANCER (SCLC) WITH A TOPOISOMERASE-I INHIBITING ANTIBODY-DRUG CONJUGATE (ADC) TARGETING TROP-2 | IMMUNOMEDICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257134-A2 | COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER | Immunomedics, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3313443-B9 | COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER | IMMUNOMEDICS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4247828-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | Institut Pasteur (FR) | 2023-09-27 | — | — | EP | disclosed |
| WO-2010093395-A1 | IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE | IMMUNOMEDICS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100104589-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | IMMUNOMEDICS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100015046-A1 | Camptothecin-Binding Moiety Conjugates | IMMUNOMEDICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7591994-B2 | Improved targetting | IMMUNOMEDICS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2009100194-A2 | CAMPTOTHECIN-BINDING MOIETY CONJUGATES | IMMUNOMEDICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-1994057-A2 | CAMPTOTHECIN-BINDING MOIETY CONJUGATES | Immunomedics, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20080171067-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | IMMUNOMEDICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080166363-A1 | Improved targetting | IMMUNOMEDICS, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2007112193-A2 | CAMPTOTHECIN-BINDING MOIETY CONJUGATES | IMMUNOMEDICS, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20060193865-A1 | Camptothecin-binding moiety conjugates | IMMUNOMEDICS, INC. | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024489-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | SI, DAD1, FUT5 | ALOX5 2482/4885CES2 4225/4885CES1 2278/4885 |
| US-20240148873-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | ERBB3, ERBB2, NTRK1 | ALOX5 4745/4885CES2 631/4885CES1 216/4885 |
| US-20060193865-A1 | Camptothecin-binding moiety conjugates | TOP2A, DCLRE1A, CYTH3 | ALOX5 4690/4885CES2 1954/4885CES1 2452/4885 |
| US-20240139324-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | ERBB3, ERBB2, NTRK1 | ALOX5 4745/4885CES2 631/4885CES1 216/4885 |
| US-20100015046-A1 | Camptothecin-Binding Moiety Conjugates | TOP2A, DCLRE1A, CYTH3 | ALOX5 4690/4885CES2 1954/4885CES1 2452/4885 |
| US-20080166363-A1 | Improved targetting | CD47, CYTH3, FCGR2A | ALOX5 4472/4885CES2 1520/4885CES1 2218/4885 |
| US-20080171067-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | CD47, BSG, SELPLG | ALOX5 4681/4885CES2 2317/4885CES1 3120/4885 |
| US-20100104589-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | CD47, CD44, DNPEP | ALOX5 4219/4885CES2 1538/4885CES1 975/4885 |
| US-20240180892-A1 | THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132) | PARP2, CD22, DOCK2 | ALOX5 4845/4885CES2 2964/4885CES1 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.